close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Metagenomi Therapeutics, Inc. - Common Stock (NQ:MGX)

0.8156 +0.1156 (+16.51%)
Delayed Quote Updated: 10:09 AM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Metagenomi Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
Appointments strengthen financial and scientific leadership to help advance multiple ultra-long-acting incretin and non-incretin therapies toward the clinic 
From ProLynx Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at Jefferies Global Healthcare Conference in London
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping pipeline and business strategy 
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at Upcoming Scientific Meetings
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Trump’s “Stargate AI” Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO
Via AB Newswire
Topics Artificial Intelligence Government
News headline image
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Announces New Appointment to its Board of Directors
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”
From Metagenomi, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.